No products in the cart
Vilon peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
Vilon (or Lyslglutamic Acid) is a peptide with apparent immunomodulatory and anti-aging bioregulation potential. It is a short peptide with just two amino acids in length, suggested to have potentially efficacious biological functions. Scientific research suggests it is also a regulator of the vascular system and encourages hemostasis. Its functions may be more widespread, with studies indicating its potential to reduce in the prevalence and growth of spontaneous tumors, though its role as an ancillary is under review. Advocates like Dr. Vladimir Anisimov believe that the peptide may be vital in research within the context of geroprotection (anti-aging) as well.
Sequence Formula: H-Lys-Glu-OH
Molecular Formula: C11N21N3O5
Molecular Weight: 257.30g/mol
Synonyms: Lysylglutamate, normophthal, Lyslglutamic acid
Vilon Peptide and Cancer Cells
Vilon, according to research, may reduce the prevalence of cancer cells in mouse models. Studies report that exposure to the peptide may potentially have reduced tumor prevalence and inhibited growth in animal research models, suggesting that Vilon may warrant further examination within the context of chemotherapeutic research, as outlined further below.
Scientific studies reported negative results when Vilon was combined with a platinum-based chemotherapeutic agent. The anti-cancer potential of Vilon and its potential within chemotherapy research is still under investigation and studies are not yet conclusive. The scientists revealed that “Vilon stimulated apoptosis both in young and old rats, but the inhibitory effect of cyclophosphan was abolished in the presence of vilon in culture media”
Vilon Peptide and Immunity
Studies in Vilon expression suggest that it may be a potent chromatin structure regulator. Studies reported that Vilon exposure may lead to potential activation of chromatin unrolling, release of repressed genes, activation of synthetic processes through the reactivation of ribosomal genes in the unrolled chromatin, and it does not appear to cause structural chromatin decondensation.
The research that lead to the development of these hypotheses further suggest that Vilon may induce the reactivation of silenced DNA genes. Generally, Chromatin presents as heterochromatin and euchromatin. Genes in the heterochromatin aspect of DNA are considered to be inaccessible to the production of proteins. The condensation of Chromatin may occur due to aging and senescence, and points to why cells and tissues lose functionality over time. The possible ability of Vilon in symbiosis with other peptide bioregulators to reactivate specific genes unrolling heterochromatin may improve immune function in elderly animal models. The researchers reported that “peptide bioregulators Epitalon, Livagen and Vilon cause activation (deheterochromatinization) of chromatin in lymphocytes of old [test subjects].”
Furthermore, Interleukin-2 may be vital in immune response coordination to microbial infection, as it may inhibit the prevalence of autoimmune reactions. The activation of interleukin-2 signaling is one suggested action of Vilon peptide in the spleen. Vilon may reinstate the immune system to a more effective state and may potentially activate lymphocytes and splenocytes—boosting natural prevention against the prevalence of autoimmune reactions.
Vilon, according to research, may enhance the propagation of CD5 T-cells in the thymus. CD5 is a potent immunohistochemical marker for T-helper cells and cytotoxic CD8 T-cells. The action of Vilon could help to influence the immune system and prevent the prevalence of autoimmune reactions. Vilon appears to function only to reactivate the immune system functions through genes that have been silenced via Chromatin changes. It doesn’t appear to actuate genes that would be silent in the cells it modifies.
Vilon Peptide and the Kidneys, Heart
Vilon’s impact on vasculature hasn’t been well studied, but some scientific studies suggest that it may exhibit action. Research in mice posits that Vilon may alter more than 36 gene expressions in the heart. When in combination with Epitalon, this number was reported to elevate to 144 genes. These results indicate that Vilon may influence gene expression trend in the cardiovascular system, which may improve hemodynamic function. Research suggests that Vilon may reduce concentrations of TGF-beta 1 in the kidneys and highly vascular organs, allowing for permeability of microvessels. The final result may be increased hemostasis during kidney failure, positing that Vilon may be impactful in the vascular system. Research in research models of diabetes reports that Vilon (Lyslglutamic Acid) may bolster coagulation by enhancing the antithrombin III anticoagulant levels and Protein C, even as it stimulates fibrinolysis. The consequence of this may be lessened blood clots in clotting-prone populations.
Vilon Peptide and Cell Aging
Exposure to the Vilon peptide appears to enhance contractile force and endurance even as it potentially decreases the prevalence of cancer cells. In mouse models, these two apparent functions of the peptide amounted to extended cell longevity. According to research, the exposure of Vilon in early life may have increased the longevity of the animal research models under observation. The hypothesis holds that the introduction of Vilon in late life may potentially reverse senescence in existing cells but may not do the same for cells that have been discarded via apoptosis. In the same sense, the exposure of Vilon early in the research models’ life may have increased a degree of protection, with modification lowered. Consequently, many cells may stay healthy for extended periods, reducing the need to change them and retaining limited stem cell lines.
Vilon’s anti-aging hypothesis is multifaceted—extending to GI functions, where it appears to better the enzyme activity in the GI tracts of aged mice. It also may improve the cell barrier functions—reducing the prevalence of leaky gut, increasing resistance to diseases, and bettering the function of the GI tract in aged mice. Vilon may mitigate nutrient extraction by enhancing glucose and glycine absorption, which will result in overall cell function and extended longevity. According to research by Dr. Vladimir N. Anisimov, two glands, the thymus and pineas, are vital regulators of cell aging. It is important to note that Vilon is classified as a thymic peptide and appears to act on lymphocytes and other cells produced in the thymus.
Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.
- Khavinson VKh, Anisimov VN. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000 May-Jun;372:261-3. PMID: 10944717.
- Barykina OP, Iuzhakov VV, Chalisova NI, Kvetnoĭ IM, Konovalov SS. Sochetannoe vliianie vilona i tsiklofosfana na transplanty opukholeĭ i éksplantaty limfoidnoĭ tkani mysheĭ i krys raznogo vozrasta [Combined effect of vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age]. Adv Gerontol. 2003;12:128-31. Russian. PMID: 14743610.
- Lezhava T, Khavison V, Monaselidze J, Jokhadze T, Dvalishvili N, Bablishvili N, Barbakadze S. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. 2004;5(2):73-9. doi: 10.1023/B:BGEN.0000025070.90330.7f. PMID: 15105581.
- Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Med News. 2006 Apr;(133):111-5. PMID: 16705247.
- Gavrisheva NA, Malinin VV, Ses TP, Kozlov KL, Panchenko AV, Titkov AY. Effect of peptide Vilon on the content of transforming growth factor-beta and permeability of microvessels during experimental chronic renal failure. Bull Exp Biol Med. 2005 Jan;139(1):24-6. doi: 10.1007/s10517-005-0202-9. PMID: 16142267.
- Kuznik BI, Isakova NV, Kliuchereva NN, Maleeva NV, Pinelis IS. [Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]. Adv Gerontol. 2007;20(2):106-15. Russian. PMID: 18306698
- Anisimov VN, Loktionov AS, Khavinson VK, Morozov VG. Effect of low-molecular-weight factors of thymus and pineal gland on life span and spontaneous tumour development in female mice of different age. Mech Ageing Dev. 1989 Sep;49(3):245-57. doi: 10.1016/0047-6374(89)90075-4. PMID: 2682058.
- Anisimov VN, Khavinson VKh. [The use of peptide bioregulators for cancer prevention: results of 35 years of research experience and perspectives]. Vopr Onkol. 2009;55(3):291-304. Russian. PMID: 19670728.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.